Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

The increasing uptake of Carvykti, driven by its attractive clinical profile and favorable outpatient dosing, has led to significant sales growth. The company’s efforts to expand manufacturing ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

Turning to our highlights. In the third quarter, we are pleased that CARVYKTI cells continued their strong momentum, delivering quarter-over-quarter growth of 53% and year-over-year growth of 87%.

Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase quarter-over-quarter. Total Revenues: $160 million, consisting of $143 million in ...

In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...

In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...

It has since been joined by Carvykti (ciltacabtagene autoleucel), which was approved by the FDA last year for the same fifth-line or later indication. Moving the use of the CAR-Ts into earlier ...